Meeting
2016 ASCO Annual Meeting
Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.
Authors
Robert Hans Ingemar Andtbacka
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Robert Hans Ingemar Andtbacka , Merrick I. Ross , Sanjiv S. Agarwala , Matthew H. Taylor , John T. Vetto , Rogerio Izar Neves , Adil Daud , Hung T. Khong , Richard S. Ungerleider , Aislyn Boran , Maki Tanaka , Kenneth F. Grossmann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9543)
DOI
10.1200/JCO.2016.34.15_suppl.9543
Abstract #
9543
Poster Bd #
148
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.
First Author: Robert Hans Ingemar Andtbacka
Poster
2019 ASCO Annual Meeting
Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
First Author: Meredith Pelster
Poster
2017 ASCO Annual Meeting
Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.
First Author: Jason Alan Chesney
Poster
2015 ASCO Annual Meeting
A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.
First Author: Howard Kaufman